/** Title: Amanta Healthcare Q1 FY27: Stable Quarter, Expansion-Led Growth Setup Slug: amanta-q1 ShortTitle: Amanta Healthcare Q1FY27 and capacity build-up CoverImageDescription: Ultra-realistic corporate finance cover image showing a clean desk with a laptop displaying a dashboard of quarterly revenue and EBITDA trend for a sterile pharma manufacturer, with two side-by-side line charts: one for quarterly revenue around 65-77 INR crore and another for EBITDA margin around 21-23 percent. In the background, a subtle industrial sterile liquids production facility scene with plastic IV bottles on a conveyor and solar panels under daylight, symbolizing capacity expansion and captive solar savings. No logos or text. */

Amanta Healthcare Q1 FY27: Stable Quarter, Expansion-Led Growth Setup

Amanta Healthcare reported a steady start to FY27, with Q1 revenue at INR 69 crore versus INR 65 crore in Q1 FY26. EBITDA stood at INR 15 crore, with management citing an EBITDA margin around 22 percent for the quarter, despite inflationary inputs and higher operating overheads taken ahead of capacity additions. PAT came in at INR 3 crore.

The quarter was less about surprise performance and more about execution timing. Management emphasized that the current asset base is running at high utilization, and the next phase of growth is tied to commissioning of new capacity in the flagship SteriPort platform, followed by an SVP expansion that is aimed at higher-margin export products. Alongside that, a newly commissioned captive solar plant is expected to structurally lower power costs from FY27 onwards.

Q1 performance: growth with cost pressure

In Q1 FY27, the company maintained revenue growth of about 5 percent year on year with broadly stable profitability. The P and L statement shows total income of INR 70 crore (including other income), total expenditure of INR 55 crore, and EBITDA of INR 15 crore. The company highlighted that employee costs increased to INR 12 crore from INR 10 crore, reflecting overheads associated with expansion readiness.

Management also discussed raw material volatility, particularly in polymers. The commentary described a sharp but short-lived spike in polymer prices, which the company addressed through price correction. For SteriPort specifically, management stated a price increase of about INR 1.50 per unit versus an estimated polymer impact of about INR 2.25 per unit, indicating partial pass-through with further absorption expected over subsequent quarters.

Business mix and what drives earnings

Amanta’s portfolio is built around sterile liquids across LVPs and SVPs, with multiple therapeutic segments including fluid therapy, formulations, diluents and injectables, ophthalmics, respiratory solutions, and irrigation solutions. The company’s product portfolio is stated at 47 products, with registrations across 120 international jurisdictions. Domestic distribution is supported by about 320 distributors and stockists.

The presentation provides a category-wise revenue share: fluid therapy at 63 percent, formulations at 17 percent, and diluents and injectables at 9 percent. In addition, management highlighted that SteriPort contributes around 44 percent of revenue, reflecting its role as a high-visibility platform within the company’s mix. For SVP, management stated it contributed around 20 percent of FY26 revenue and operates at EBITDA margins of 22 to 27 percent.

A key operational datapoint is utilization. FY26 utilization was reported at around 91 percent for LVP (excluding SteriPort), 98 percent for SVP, and 90 percent for SteriPort. This matters because expansion-led growth, especially in sterile manufacturing, is most attractive when base assets are already operating near peak.

Expansion cycle: SteriPort and SVP commissioning timelines

The near-term catalyst is SteriPort Line 3. The presentation states that SteriPort (LVP) expansion in capacity is expected to generate incremental revenue of INR 110 to 120 crore per year, along with EBITDA margin expansion of 3 to 4 percent driven by fixed cost leverage from adding a new line within the same plant.

However, management acknowledged that the SteriPort expansion was delayed. The call attributed the shift mainly to civil construction delays, pushing commencement from Q1 to Q2 FY27. Management further stated that FDA plan approval had been received, validation and qualification activities were in progress, and the company intended to start commercial production in the last week of August 2026, subject to inspection.

On financial implications, management discussed depreciation and returns. Incremental depreciation from the SteriPort line was indicated at around INR 4.5 crore annually. The CFO added that total company depreciation could increase by about INR 6 crore annually versus FY26 once SteriPort, SVP and solar assets are fully capitalized. On returns, management agreed with an investor estimate of incremental ROCE for SteriPort line at about 16 to 17 percent (ballpark).

The second leg is SVP expansion. The presentation indicates SVP capacity expansion from 20.9 crore units (FY25) to 31.7 crore units (FY27P). Management stated the new SVP facility is expected to commence operations in Q4 FY27, and on the call indicated a Feb to March 2027 window. Management also discussed a pipeline of 20 products under development, with one inhalation product expected to be commercialized around mid-September 2026.

Solar plant: a structural cost lever

A separate lever is energy cost. The company has implemented a 10.8 MW captive solar power plant. The presentation quantifies the project at INR 34.8 crore total cost, largely debt-funded, with expected annual savings of INR 9 crore and a pre-interest payback period of 3.6 years. Management stated the project was commissioned in June 2026, with benefits expected to be visible from FY27 onwards.

On the call, management clarified that the solar savings are incremental to the operating leverage from SteriPort Line 3, and indicated that EBITDA margin expansion of about 4 to 5 percent was being targeted when including the solar benefit.

Takeaways

Amanta Healthcare’s Q1 FY27 numbers were stable, with growth achieved on a high-utilization base, while near-term margins absorbed polymer volatility and expansion overheads. The investment case over the next few quarters is tied to execution: SteriPort Line 3 ramp-up from late August 2026, visible impact from Q3 onwards, and SVP commissioning in Q4 FY27 with a product pipeline focused on inhalation solutions and other sterile unit doses.

The solar commissioning adds a quantified, non-cyclical lever to operating margins. If commissioning timelines hold and the new capacities reach planned utilization, the company’s stated peak revenue and margin commentary for FY28 becomes more testable in reported numbers.